Ferrer and Prilenia Sign Agreement for Pridopidine Co-Development and Commercialization
Apr 28, 2025•3 months ago
Contract Type
agreement
Description
Ferrer, a pharmaceutical company with a focus on rare neurological diseases, has entered into a strategic co-development and license agreement with Prilenia Therapeutics B.V., a clinical-stage biotech company, for the development, manufacture, and commercialization of Pridopidine. Pridopidine, an orally administered sigma-1 receptor agonist, is a promising candidate for the treatment of Huntington’s Disease.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months